Tag:

India

Latest Headlines

Latest Headlines

MSF urges Indian PM to stand firm against Big Pharma's patent lobbying

As Indian Prime Minister Narendra Modi travels to the U.S. to meet with officials, Doctors Without Borders (MSF) has one message for him: Don't back down on drug patents.

Report: Indian government to take legal action over drug quality paper

The Indian government has begun legal action against think tank the American Enterprise Institute (AEI) over a paper on drug quality, The Times of India reports.

Apotex tries to 'set the record straight' after Health Canada quarantine request

The three-way spat between Health Canada, local media and Apotex is rumbling on. Late last week Health Canada won an equivocal thumbs-up from the media for its move to quarantine products from one of Apotex's Indian plants, only for the generic drugmaker to hit back with a press release to "set the record straight."

Strides and Shasun plan merger to create big, 'de-risking' production network

With a string of regulatory actions against manufacturers showing the dangers of relying heavily on one production plant, India's Strides Arcolab and Shasun Pharmaceuticals plan to merge to spread the risk.

GVK accused of tampering with data in Indian clinical trials

Indian CRO GVK Biosciences is working to get back in the good graces of European regulators after inspectors found evidence that its employees doctored clinical trial results.

India reins in agency's ability to cap drug prices

Price caps on "essential drugs" in India have been a sore point with domestic as well as Big Pharma players. The industry was further enraged when an Indian agency in May assumed the authority to add other products to the 350 already restricted. But the government of Prime Minister Narendra Modi is reining in the National Pharmaceutical Pricing Authority (NPPA), suggesting he may have a less populous approach to the industry than his predecessor.

AstraZeneca opens Indian IT center as 13-year outsourcing experiment nears end

AstraZeneca is following the well-trodden path of offshoring part of its IT to India. But unlike some of its peers--and in a reversal of its own strategy--the Big Pharma is adding in-house capacity and lessening its reliance on IT service providers.

More FDA issues arise for Hospira in India

About three months before Hospira closed on its acquisition of an API plant from India's Orchid Chemicals & Pharmaceuticals, FDA inspectors made a visit to the facility in Waluj. They had concerns with what they found.

India's top drugmakers forecast to invest $8B in production upgrades

India's 20 largest drug manufacturers are forecast to boost their plant investments by 40%  by 2017-18,  to more than Rs 50,000 crore ($8.3 billion), as they look to improve quality and chase new patent expirations.

UPDATED: Merck KGaA negotiates huge production deal with Lupin

Merck is investing €80 million ($107.67 million) in a new plant in China to make treatments for diabetes and other conditions and to realize its aspirations there. But it appears it is looking to India as a way to cut production costs on some of its older products.